The 2022 ASCO Annual Meeting brings together colleagues from across the world with different disciplines and subspecialties related to cancer care. The meeting will have a hybrid format with both in-person and online attendance, featuring 200+ sessions that will compliment this year’s program theme: Advancing Equitable Cancer Care Through Innovation.
Whether you are attending the meeting in Chicago or online, you can join more than 85 livestream sessions from anywhere; discover 2,500+ poster presentations; take notes and download session slides; and participate in live Q&A and sessions with polling.
Taylor & Francis is a STM publisher, offering innovative publishing options and services that fit the evolving needs of authors and researchers worldwide. We connect you with the latest oncology research contributing to advancements in etiology, prevention, treatment and care, and diagnosis of cancer. Explore our oncology journal portfolio below and discover where you and your research belong next. This year we also publish a number of new editions of flagship titles in Gynecologic Oncology (such as Robert Bristow’s Surgery for Ovarian Cancer, 4th edition) and Hematologic Oncology (such as Wojciech Gorczyca’s Flow Cytometry in Neoplastic Hematology, 4th edition).
Open access publishing makes academic articles permanently available online. Anyone, anywhere can read and build upon your research, increasing the reach and impact of your published work.
You can choose to publish open access in a fully OA journal or in an Open Select journal, known as hybrid publishing. We offer a variety of publishing models and licenses for you to choose across our journal portfolio from Taylor & Francis and Dove Medical Press, and publishing platform, F1000Research.
Open access is great for readers because it gives them immediate access to the latest research, but there are also many advantages to you, the author. Click the link below to learn more about the benefits of publishing open access.
Top Downloaded Articles
External validation of the MSKCC nomogram to estimate five-year overall survival after surgery for stage I–III colon cancer in a Dutch population
Identification of prognostic biomarkers in papillary renal cell carcinoma and PTTG1 may serve as a biomarker for predicting immunotherapy response
Colon cancer stem cells: Potential target for the treatment of colorectal cancer
Treatment of Advanced/Metastatic Melanoma in the United States and Western Europe: Results of the CancerMPact Survey
Immunotherapy in soft tissue sarcoma: current evidence and future perspectives in a variegated family of different tumor
Feasibility study of metabolically supported chemotherapy with weekly carboplatin/paclitaxel combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in metastatic non-small cell lung cancer
The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt
Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa
Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection
A fasting-mimicking diet and vitamin C: turning anti-aging strategies against cancer